Showing results (331-340 of 698) with videos related to
Sort By:
Pageof 70
BMJ Open Diabetes Research & Care|October 14, 2021
Cardiovascular autonomic neuropathy and the impact on progression of diabetic kidney disease in type 1 diabetesTheis Bjerre-Christensen, Signe A Winther, Nete Tofte, et al.Diabetes Care|January 29, 2011
Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up studyJohanna W Nin, Anders Jorsal, Isabel Ferreira, et al.Journal of the American Society of Nephrology : JASN|May 2, 2008
Urinary proteomics in diabetes and CKDKasper Rossing, Harald Mischak, Mohammed Dakna, et al.Cardiovascular Diabetology|September 24, 2016
Cholesterol remnants and triglycerides are associated with decreased myocardial function in patients with type 2 diabetesPeter Godsk Jørgensen, Magnus Thorsten Jensen, Tor Biering-Sørensen, et al.Plos One|April 27, 2018
Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes - An observational follow-up studyMarie Frimodt-Møller, Bernt Johan von Scholten, Henrik Reinhard, et al.Diabetes Care|September 12, 2022
Endotrophin as a Marker of Complications in a Type 2 Diabetes CohortNinna Hahn Tougaard, Alexandra Louise Møller, Pernille Falberg Rønn, et al.Diabetes, Obesity & Metabolism|August 13, 2025
Targeting visceral and ectopic adiposity: Pharmacological and surgical interventions beyond global weight lossMustafa Guldan, Lasin Ozbek, Sama M Abdel-Rahman, et al.Frontiers in Molecular Biosciences|September 19, 2023
Endotrophin as a risk marker of mortality and kidney complications in a type 1 diabetes cohortAlexandra Louise Møller, Ninna Hahn Tougaard, Daniel Guldager Kring Rasmussen, et al.The Lancet. Diabetes & Endocrinology|August 8, 2017
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysisKåre I Birkeland, Marit E Jørgensen, Bendix Carstensen, et al.Diabetes, Obesity & Metabolism|August 4, 2017
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational studyFrederik Persson, Thomas Nyström, Marit E Jørgensen, et al.Pageof 70